AIDX20/20 Biolabs Inc. Common Stock
0.5543USD+8.99%Mkt Cap: 7.08M $P/E: —4d ago
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detect…
Industry Peers
Medical Devices$203.22BUSDP/E 37.8
$125.74BUSDP/E 34.0
$118.91BUSDP/E 24.9
$71.03BUSDP/E 19.8
$48.43BUSDP/E 19.9
$52.11BUSDP/E 53.9
$34.85BUSDP/E 36.5
$34.04BUSDP/E 17.2
$25.08BUSDP/E 20.7
$26.90BUSDP/E 20.7
$23.19BUSDP/E 29.1
$19.26BUSDP/E 24.5
$12.75BUSDP/E 79.7
$12.40BUSDP/E 20.1
$11.29BUSDP/E 21.5
$10.95BUSD
$9.84BUSDP/E 20.0
$10.28BUSDP/E 27.5
$10.22BUSDP/E 46.5
$8.82BUSDP/E 25.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 How The Healwell AI (TSX:AIDX) Investment Story Is Shifting With Recut Targets And Growth Assumptions Healwell AI is back in focus after analysts trimmed fair value from CA$3.45 to CA$2.85, roughly a 17% reset to their modeled price target. Recent research has centered on recalibrating these targets, with some moves to about CA$3.10 as analysts weigh growth expectations against execution and valuation risk. Read on to see how you can track these shifting targets and what they might mean for following the evolving Healwell AI story. Analyst Price Targets don't always capture the full story... | ||